Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency
Emmaus Life Sciences announced today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has accepted the company's pediatric investigation plan (PIP) for its treatment of sickle cell disease. The decision allows Emmaus to proceed with the submission of a Marketing Authorization Application (MAA).
“The approval of our PIP represents a significant step forward in our efforts to bring this treatment to market in the European Union (EU),” said Yutaka Niihara, MD, MPH, Chairman and Chief Executive Officer of Emmaus Life Sciences, “We look forward to submitting our MAA in the near term and hope to provide sickle cell patients in the EU with a new treatment option once we complete the regulatory process.”
The EMA requires companies seeking to register new medicines to agree with the PDCO on a PIP that outlines a clinical development program for studying the investigational product in the pediatric population. An accepted PIP is required before a company can file an MAA for a new drug in the EU.
On July 7, 2017, the United States (U.S.) Food and Drug Administration approved Endari™ (L-glutamine oral powder), for its use in the U.S.
Emmaus has obtained both Orphan Drug designation in the U.S. and Orphan Medicinal Product designation in the E.U.
About Sickle Cell Disease
Sickle Cell Disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with Sickle Cell Disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to a variety of other adverse outcomes such as acute chest syndrome that requires hospitalization. Sickle Cell Disease is an orphan disease, affecting approximately 100,000 patients in the U.S. and millions worldwide with significant unmet medical needs.
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10%) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included 1 case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than 5 years of age has not been established.
For more information, please see full Prescribing Information of Endari at www.ENDARIrx.com/Repository/Prescribing%20information.pdf
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
for Emmaus Life Sciences
Lori Teranishi, 510-290-6160
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Javier Gómez Noya Chooses ROKA Eyewear26.4.2018 18:15 | Pressemelding
ROKA, the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya, expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/ Javier Gómez Noya Chooses ROKA Eyewear (Photo: Business Wire) “I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of
Egyptian Singer Becomes First Woman to Perform Before a Mixed Crowd in Saudi Arabia26.4.2018 17:55 | Pressemelding
History was made in Saudi Arabia on Wednesday as a female singer performed before a mixed audience for the first time in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006471/en/ Egypt’s National Arab Music Ensemble of the Egyptian Opera House debuted in Saudi Arabia with the singer Nihad Fathy performing before a 2,500-strong audience in Riyadh. This is the first time a woman singer performed on stage in the Kingdom before a mixed crowd. (Photo courtesy of GCA Saudi Arabia.) Egypt’s National Arab Music Ensemble (AME) of the Egyptian Opera House debuted in the Kingdom with the singer Nihad Fathy performing before a 2,500-strong audience at King Fahad Cultural Center in Riyadh. The crowd broke into a rapturous applause as she took to the stage. The Egyptian Opera House ensemble, which was led by famous conductor Moustafa Helmy, comprised 45 male and female musicians and singers, including the star singers A
Pharnext Appoints Amit Kohli as Chief Operating Officer26.4.2018 16:00 | Pressemelding
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Amit Kohli, a senior healthcare industry executive, as Chief Operating Officer (COO). Mr. Kohli is responsible for leading Pharnext’s corporate strategy and operations. “Amit is a seasoned leader with over 20 years’ experience in the healthcare industry, and we are thrilled he is joining Pharnext,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are deeply impressed with Amit’s results-oriented track record, and his ability to drive business strategy and operations across the pharma, medtech and clinical diagnostics sectors. We believe Pharnext will greatly benefit from his extensive cross-functional leadership experience especially as our first-in-class orphan drug, PXT3003, for the
Leading Marine Container Leasing Management Team Launches Global Container International26.4.2018 15:33 | Pressemelding
Jeffrey Gannon and Adrian Dunner, in partnership with investment vehicles managed by Wafra Inc., today announced the formation of Global Container International LLC (“Global”), a new marine container leasing platform headquartered in Boston, Massachusetts and with representation in Hong Kong, Shanghai, Singapore, Antwerp, Taipei, and Seoul. With a near-term goal of building a fleet of 1 million TEU (twenty-foot equivalent units), Global is positioned to provide its customers a reliable alternative source of capital and containers for lease. Jeffrey Gannon serves as Chief Executive Officer of Global, and Adrian Dunner serves as Chief Operating Officer. Together, they offer clients a combined 50 years of experience backed by successful track records in the container leasing industry. Global will invest in marine containers and related equipment made available for lease under a wide range of structures to meet customer needs. Investments will include new build containers, portfolio purcha
TimeXtender Discovery Hub® is Now Microsoft Azure Certified26.4.2018 14:00 | Pressemelding
TimeXtender, a recognized global software company enabling instant access to any type of data in the organization to support advanced analytics and artificial intelligence (AI), today announced that its Discovery Hub® solution has been tested, approved and certified for readiness and compatibility to run in Microsoft Azure environments. With this certification, Discovery Hub® is now a trusted application that is available in the Microsoft Azure Marketplace. The Azure Marketplace is an extensive catalog of products from independent software vendors (ISVs). Azure Marketplace allows IT professionals and developers to confidently search for Microsoft Azure certified products and solutions. “To be published in the Azure Marketplace, a solution goes through a number of certification steps to validate the platform, solution and software,” said Heine Krog Iversen, CEO at TimeXtender. “Given these requirements, we’re pleased that Discovery Hub® has been certified to run on Microsoft Azure. This
Andersen Global Announces Collaboration in Peru26.4.2018 13:30 | Pressemelding
Andersen Global continues its expansion in Latin America through a Collaboration Agreement with Picon & Asociados, a tax and legal practice that encompasses a full range of private and corporate services. Picon & Asociados, located in Lima, enhances Andersen’s provision of best-in-class service globally. Jorge Picon leads the team in Peru. “Picon & Asociados is an excellent fit for our global organization and the collaboration addresses another key market in South America,” remarked Mark Vorsatz, Global Chairman and Andersen Tax LLC CEO. “The practice, which includes nearly 40 professionals, provides us with added legal capabilities and enhances our core tax business in the region.” Jorge added, “Creating value for our clients by providing high quality, specialized tax and legal services is a top priority, and working with professionals that share this mindset is very important to us. Our team is committed to providing best-in-class solutions for our clients and we look forward to coll